This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snydman, D. R.
Right arrow Articles by Boyce, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snydman, D. R.
Right arrow Articles by Boyce, J. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2000, p. 3447-3450, Vol. 44, No. 12
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Comparative In Vitro Activities of Daptomycin and Vancomycin against Resistant Gram-Positive Pathogens

D. R. Snydman,1,* N. V. Jacobus,1 L. A. McDermott,1 J. R. Lonks,2 and J. M. Boyce2

New England Medical Center, Boston, Massachusetts,1 and Miriam Hospital, Academic Medical Center, Lifespan, Providence, Rhode Island2

Received 18 February 2000/Returned for modification 13 May 2000/Accepted 21 August 2000

The in vitro activity of daptomycin against 224 current gram-positive clinical isolates including vancomycin-resistant Enterococcus faecium (VREF), methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus spp. (MRSS), and penicillin-resistant Streptococcus pneumoniae (PRSP) was evaluated. The MICs at which 90% of isolates are inhibited for daptomycin and vancomycin, respectively, were as follows: MRSA, 1 and 2 µg/ml; MRSS, 1 and 4 µg/ml; PRSP, 1 and 0.5 µg/ml; and VREF, 2 and >64 µg/ml. Daptomycin was bactericidal against 82% of 17 VREF isolates. The antibacterial activity of daptomycin was strongly dependent on the calcium concentration of the medium. Daptomycin was active against all gram-positive cocci tested.

* Corresponding author. Mailing address: Box 238, New England Medical Center, 750 Washington St., Boston, MA 02111. Phone: (617) 636-5788. Fax: (617) 636-8525. E-mail: dsnydman{at}lifespan.org.

Antimicrobial Agents and Chemotherapy, December 2000, p. 3447-3450, Vol. 44, No. 12
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Moise, P. A, Hershberger, E., Amodio-Groton, M. I, Lamp, K. C (2009). Safety and Clinical Outcomes when Utilizing High-Dose (>=8 mg/kg) Daptomycin Therapy. The Annals of Pharmacotherapy 43: 1211-1219 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Firsov, A. A., Smirnova, M. V., Lubenko, I. Yu., Vostrov, S. N., Portnoy, Y. A., Zinner, S. H. (2006). Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 58: 1185-1192 [Abstract] [Full Text]  
  • Jevitt, L. A., Thorne, G. M., Traczewski, M. M., Jones, R. N., McGowan, J. E. Jr., Tenover, F. C., Brown, S. D. (2006). Multicenter Evaluation of the Etest and Disk Diffusion Methods for Differentiating Daptomycin-Susceptible from Non-Daptomycin-Susceptible Staphylococcus aureus Isolates.. J. Clin. Microbiol. 44: 3098-3104 [Abstract] [Full Text]  
  • Fowler, V. G. Jr., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., Cabell, C. H., Link, A. S., DeMeyer, I., Filler, S. G., Zervos, M., Cook, P., Parsonnet, J., Bernstein, J. M., Price, C. S., Forrest, G. N., Fatkenheuer, G., Gareca, M., Rehm, S. J., Brodt, H. R., Tice, A., Cosgrove, S. E., the S. aureus Endocarditis and Bacteremia Study Gr, (2006). Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus.. NEJM 355: 653-665 [Abstract] [Full Text]  
  • Gerber, P., Stucki, A., Acosta, F., Cottagnoud, M., Cottagnoud, P. (2006). Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 57: 720-723 [Abstract] [Full Text]  
  • D'Costa, V. M., McGrann, K. M., Hughes, D. W., Wright, G. D. (2006). Sampling the Antibiotic Resistome. Science 311: 374-377 [Abstract] [Full Text]  
  • Schriever, C. A., Fernandez, C., Rodvold, K. A., Danziger, L. H. (2005). Daptomycin: A novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 62: 1145-1158 [Abstract] [Full Text]  
  • Steenbergen, J. N., Alder, J., Thorne, G. M., Tally, F. P. (2005). Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55: 283-288 [Abstract] [Full Text]  
  • Credito, K., Lin, G., Ednie, L. M., Appelbaum, P. C. (2004). Antistaphylococcal Activity of LBM415, a New Peptide Deformylase Inhibitor, Compared with Those of Other Agents. Antimicrob. Agents Chemother. 48: 4033-4036 [Abstract] [Full Text]  
  • Lai, J.-J., Brodeur, S. K (2004). Physical and Chemical Compatibility of Daptomycin with Nine Medications. The Annals of Pharmacotherapy 38: 1612-1616 [Abstract] [Full Text]  
  • Fluit, A. C., Schmitz, F.-J., Verhoef, J., Milatovic, D. (2004). In Vitro Activity of Daptomycin against Gram-Positive European Clinical Isolates with Defined Resistance Determinants. Antimicrob. Agents Chemother. 48: 1007-1011 [Abstract] [Full Text]  
  • Jorgensen, J. H., Crawford, S. A., Kelly, C. C., Patterson, J. E. (2003). In Vitro Activity of Daptomycin against Vancomycin-Resistant Enterococci of Various Van Types and Comparison of Susceptibility Testing Methods. Antimicrob. Agents Chemother. 47: 3760-3763 [Abstract] [Full Text]  
  • Restrepo, M. I., Velez, J. A., McElmeel, M. L., Whitney, C. G., Jorgensen, J. H. (2003). Activity of Daptomycin against Recent North American Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 2974-2977 [Abstract] [Full Text]  
  • Bemer, P., Juvin, M.-E., Bryskier, A., Drugeon, H. (2003). In Vitro Activities of a New Lipopeptide, HMR 1043, against Susceptible and Resistant Gram-Positive Isolates. Antimicrob. Agents Chemother. 47: 3025-3029 [Abstract] [Full Text]  
  • Silverman, J. A., Perlmutter, N. G., Shapiro, H. M. (2003). Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 2538-2544 [Abstract] [Full Text]  
  • Laganas, V., Alder, J., Silverman, J. A. (2003). In Vitro Bactericidal Activities of Daptomycin against Staphylococcus aureus and Enterococcus faecalis Are Not Mediated by Inhibition of Lipoteichoic Acid Biosynthesis. Antimicrob. Agents Chemother. 47: 2682-2684 [Abstract] [Full Text]  
  • Vaudaux, P., Francois, P., Bisognano, C., Li, D., Lew, D. P., Schrenzel, J. (2003). Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 52: 89-95 [Abstract] [Full Text]  
  • Critchley, I. A., Blosser-Middleton, R. S., Jones, M. E., Thornsberry, C., Sahm, D. F., Karlowsky, J. A. (2003). Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001. Antimicrob. Agents Chemother. 47: 1689-1693 [Abstract] [Full Text]  
  • Sakoulas, G., Eliopoulos, G. M., Alder, J., Eliopoulos, C. T. (2003). Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcusaureus. Antimicrob. Agents Chemother. 47: 1714-1718 [Abstract] [Full Text]  
  • Dvorchik, B. H., Brazier, D., DeBruin, M. F., Arbeit, R. D. (2003). Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects. Antimicrob. Agents Chemother. 47: 1318-1323 [Abstract] [Full Text]  
  • Critchley, I. A., Draghi, D. C., Sahm, D. F., Thornsberry, C., Jones, M. E., Karlowsky, J. A. (2003). Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 51: 639-649 [Abstract] [Full Text]  
  • Petersen, P. J., Bradford, P. A., Weiss, W. J., Murphy, T. M., Sum, P. E., Projan, S. J. (2002). In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive Pathogens. Antimicrob. Agents Chemother. 46: 2595-2601 [Abstract] [Full Text]  
  • Silverman, J. A., Oliver, N., Andrew, T., Li, T. (2001). Resistance Studies with Daptomycin. Antimicrob. Agents Chemother. 45: 1799-1802 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»